Suppr超能文献

垂体腺瘤中Mir-23b和miR-130b的表达下调。

Mir-23b and miR-130b expression is downregulated in pituitary adenomas.

作者信息

Leone Vincenza, Langella Concetta, D'Angelo Daniela, Mussnich Paula, Wierinckx Anne, Terracciano Luigi, Raverot Gerald, Lachuer Joel, Rotondi Sandra, Jaffrain-Rea Marie-Lise, Trouillas Jacqueline, Fusco Alfredo

机构信息

Istituto di Endocrinologia ed Oncologia Sperimentale del CNR, c/o Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Scuola di Medicina e Chirurgia di Napoli, Università degli Studi di Napoli "Federico II", Naples, Italy.

INSERM U1052, Centre de Recherche en Cancerologie de Lyon, F-69000 Lyon, France and University Lyon, F-69000 Lyon, France; Profilexpert UNIV-US7 INSERM-UMS 3453 CNRS Lyon, France.

出版信息

Mol Cell Endocrinol. 2014 Jun 5;390(1-2):1-7. doi: 10.1016/j.mce.2014.03.002. Epub 2014 Mar 28.

Abstract

MicroRNA (miRNA) deregulation plays a critical role in tumorigenesis. miR-23b and miR-130b are induced by thyrotropin in thyroid cells in a cAMP-dependent manner. The aim of our work has been to investigate the possible role of miR-23b and miR-130b in pituitary tumorigenesis. We have analyzed their expression in a panel of pituitary adenomas (PAs) including GH and NFPA adenomas. We report that miR-23b and miR-130b are drastically reduced in GH, gonadotroph and NFPA adenomas in comparison with normal pituitary gland. Interestingly, the overexpression of miR-23b and miR-130b inhibits cell proliferation arresting the cells in the G1 and G2 phase of the cell cycle, respectively. Moreover, we demonstrate that miR-23b and miR-130b target HMGA2 and cyclin A2 (CCNA2) genes, respectively. Finally, downregulation of miR-23b and miR-130b expression is associated with increased levels of their respective targets in human PAs. These findings suggest that miR-23b and miR-130b downregulation may contribute to pituitary tumorigenesis.

摘要

微小RNA(miRNA)失调在肿瘤发生中起关键作用。miR - 23b和miR - 130b在甲状腺细胞中由促甲状腺激素以cAMP依赖的方式诱导产生。我们研究的目的是探讨miR - 23b和miR - 130b在垂体肿瘤发生中的可能作用。我们分析了它们在一组垂体腺瘤(PA)中的表达,包括生长激素(GH)腺瘤和无功能垂体腺瘤(NFPA)。我们报告称,与正常垂体相比,miR - 23b和miR - 130b在GH腺瘤、促性腺激素腺瘤和NFPA腺瘤中显著降低。有趣的是,miR - 23b和miR - 130b的过表达分别抑制细胞增殖,使细胞停滞在细胞周期的G1期和G2期。此外,我们证明miR - 23b和miR - 130b分别靶向HMGA2和细胞周期蛋白A2(CCNA2)基因。最后,miR - 23b和miR - 130b表达的下调与人类PA中其各自靶标的水平升高有关。这些发现表明,miR - 23b和miR - 130b的下调可能促成垂体肿瘤的发生。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验